The role of citicoline in cognitive impairment: Pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives

Clinical Interventions in Aging

Volumn 10, Issue , 2015, Pages 1421-1429

  Gareri, Pietro ^a   Castagna, Alberto ^a   Cotroneo, Antonino Maria ^b   Putignano, Salvatore ^c   De Sarro, Giovambattista ^d   Bruni, Amalia Cecilia ^a  

^a ASP Catanzaro   (Italy)

^b ASL 2 Turin   (Italy)

^c Elderly Assistance Unit   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Citicoline; Cognitive impairment; Elderly; Neurodegeneration; Neuroprotective effects; Sirtuins

Indexed keywords

ALPHA SYNUCLEIN; CHOLINE; CITICOLINE; CYTIDINE; PLACEBO; PROTEIN KINASE; SIRTUIN 1; NOOTROPIC AGENT;

COGNITIVE DEFECT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; HEADACHE; HUMAN; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PARESTHESIA; PHARMACODYNAMICS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SENSORY DYSFUNCTION; COGNITION DISORDERS;

COGNITION DISORDERS; CYTIDINE DIPHOSPHATE CHOLINE; HUMANS; NOOTROPIC AGENTS;

EID: 84940979687     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S87886     Document Type: Review

References (46)

1. Secades JJ, Frontera G. CDP-choline: pharmacological and clinical review. Methods Find Exp Clin Pharmacol. 1995;17(suppl B):1-54.
2. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;18(2):CD000269.
3. Hurtado O, Lizasoain I, Moro MÁ. Neuroprotection and recovery: recent data at the bench on citicoline. Stroke. 2011;42(suppl1):S33-S35.
4. Grieb P. Neuroprotective properties of citicoline: facts, doubts and unresolved issues. CNS Drugs. 2014;28(3):185-193.
5. Alvarez-Sabín J, Ortega G, Jacas C, et al. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment. Cerebrovasc Dis. 2013;35(2):146-154.
6. Secades JJ. Citicoline: pharmacological and clinical review, 2010 update. Rev Neurol. 2011;52(suppl 2):S1-S62.
7. Alvarez-Sabin J, Roman GC. Citicoline in vascular cognitive impairment and vascular dementia after stroke. Stroke. 2011;42:S40-S43.
8. García-Cobos R, Frank-García A, Gutiérrez-Fernández M, Díez-Tejedor E. Citicoline, use in cognitive decline: vascular and degenerative. J Neurol Sci. 2010;299(1-2):188-192.
9. Fioravanti M, Buckley AE. Citicoline (Cognizin) in the treatment of cognitive impairment. Clin Interv Aging. 2006;1(3):247-251.
10. Putignano S, Gareri P, Castagna A, et al. Retrospective and observational study to assess the efficacy of citicoline in elderly patients suffering from stupor related to complex geriatric syndrome. Clin Interv Aging. 2012;7:113-118.
11. Cotroneo AM, Castagna A, Putignano S, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin Interv Aging. 2013;8:131-137.
12. Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol. 2006;28(suppl B):1-56.
13. Franco-Maside A, Caamaño J, Gómez MJ, Cacabelos R. Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer’s disease. Methods Find Exp Clin Pharmacol. 1994;16(8):597-607.
14. Caamaño J, Gómez MJ, Franco A, Cacabelos R. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer’s disease. Methods Find Exp Clin Pharmacol. 1994;16(3):211-218.
15. Fernández-Novoa L, Alvarez XA, Franco-Maside A, Caamaño J, Cacabelos R. CDP-choline-induced blood histamine changes in Alzheimer’sdisease. Methods Find Exp Clin Pharmacol. 1994;16(4):279-284.
16. Cacabelos R, Alvarez XA, Franco-Maside A, Fernández-Novoa L, Caamaño J. Effect of CDP-choline on cognition and immune function in Alzheimer’s disease and multi-infarct dementia. Ann N Y Acad Sci. 1993;695:321-323.
17. Alvarez XA, Mouzo R, Pichel V, et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer’s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol. 1999;21(9):633-644.
18. Bellizzi D, Dato S, Cavalcante P, et al. Characterization of a bidirectional promoter shared between two human genes related to aging: SIRT3 and PSMD13. Genomics. 2007;89(1):143-150.
19. Donmez G. Sirtuins as possible targets in neurodegenerative diseases. Curr Drug Targets. 2013;14:644-647.
20. Donmez G, Guarente L. Aging and disease: connections to sirtuins. Aging Cell. 2010;9:285-290.
21. Ma CY, Yao MJ, Zhai QW, Jiao JW, Yuan XB, Poo MM. SIRT1 suppresses self-renewal of adult hippocampal neural stem cells. Development. 2014;141:4697-4709.
22. Kim SH, Lu HF, Alano CC. Neuronal SIRT3 protects against excitotoxic injury in mouse cortical neuron culture. PLoS One. 2011;6:e14731.
23. D’Aquila P, Rose G, Panno ML, Passarino G, Bellizzi D. SIRT3 gene expression: a link between inherited mitochondrial DNA variants and oxidative stress. Gene. 2012;497(2):323-329.
24. Zhang F, Wang S, Gan L, et al. Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol. 2011;95:373-395.
25. Donmez G, Wang D, Cohen D, Guarente L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell. 2010;142:320-332.
26. Donmez G, Outeiro TF. SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol Med. 2013;5:344-352.
27. Min SW, Cho SH, Zhou Y, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010;67:953-966.
28. Donmez G. The neurobiology of sirtuins and their role in neurodegeneration. TIPS. 2012;33(9):494-501.
29. Albensi BC, Mattson MP. Evidence for the involvement of TNF and NF-kB in hippocampal synaptic plasticity. Synapse. 2010;35(2):151-159.
30. Donmez G, Arun A, Chung CY, McLean PJ, Lindquist S, Guarente L. SIRT1 protects against α-synuclein aggregation by activating molecular chaperones. J Neurosci. 2012;32(1):124-132.
31. Polito L, Kehoe PG, Davin A, et al. The SIRT2 polymorphism rs10410544 and risk of Alzheimer’s disease in two Caucasian case control cohorts. Alzheimers Dement. 2013;9(4):392-399.
32. Hurtado O, Hernández-Jiménez M, Zarruk JG, et al. Citicoline (CDP-choline) increases Sirtuin1 expression concomitant to neuroprotection in experimental stroke. J Neurochem. 2013;126:816-819.
33. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family and NAD-dependent deacetylases by phenotypic screening. J Biol Chem. 2001;276:38837-38843.
34. Hernández-Jiménez M, Hurtado O, Cuartero MI, et al. Silent information regulator 1 (SIRT1) protects the brain against cerebral ischemic damage. Stroke. 2013;44(8):2333-2337.
35. Krupinski J, Slevin M, Badimon L. Citicoline inhibits MAP kinase signalling pathways after focal cerebral ischaemia. Neurochem Res. 2005;30(8):1067-1073.
36. Lozano-Fernandez R. Efficacy and safety of oral CDP-choline. Drug surveillance study in 2,817 cases. Arzneimittelforschung. 1983;33(7A):1073-1080.
37. Secades JJ. CDP-choline: update and review of its pharmacology and clinical use. Methods Find Exp Clin Pharmacol. 2002; 24(suppl B):1-53.
38. Cacabelos R, Caamaño J, Gómez MJ, Fernández-Novoa L, Franco-Maside A, Alvarez XA. Therapeutic effects of CDP-choline in Alzheimer’s disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. Ann N Y Acad Sci. 1996; 777:399-403.
39. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604-607.
40. Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke. 1994;25(11):2220-2226.
41. Kasner SE, Chalela JA, Luciano JM, et al. Reliability and validity of estimating the NIH stroke scale score from medical records. Stroke. 1999;30(8):1534-1537.
42. Sulter G, Steen C, De Keyser J. Use of the Barthel Index and modified Rankin Scale in acute stroke trials. Stroke. 1999;30(8):1538-1541.
43. Zafonte RD, Bagiella E, Ansel BM, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: citicoline brain injury treatment trial (COBRIT). JAMA. 2012;308(19):1993-2000.
44. Dávalos A, Alvarez-Sabín J, Castillo J, et al; International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012;380(9839):349-357.
45. D’Orlando KJ, Sandage BW Jr. Citicoline (CDP-choline): mechanism of action and effects in ischemic brain injury. Neurol Res. 1995;17:281-284.
46. Dinsdale JR, Griffiths GK, Castelló J, Maddock J, Ortiz JA, Aylward M. CDP-choline: repeated oral dose tolerance studies in adult healthy volunteers. Arzneimittelforschung. 1983;33(7A):1061-1065.